Related Experiment Video
Updated: Aug 6, 2026

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
Published on: June 23, 2026
Protein expression profiling identifies cyclophilin A as a molecular target in Fhit-mediated tumor suppression
1Comprehensive Cancer Center and Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University, Room 455C, Wiseman Hall, 410 West 12th Avenue, Columbus, 43210, USA.
Abstract:
Loss of fragile histidine triad (Fhit) expression is often associated with human malignancies, and Fhit functions as a tumor suppressor in controlling cell growth and apoptosis, although specific signal pathways are still undefined. We have used a proteomic approach to define proteins in the Fhit-mediated tumor suppression pathway. Because substitution of Tyr(114) (Y114) with phenylalanine (Y114F) diminishes Fhit functions, we did protein expression profiling to identify proteins differentially expressed in Fhit-negative H1299 lung cancer cells infected with wild-type (Ad-FHIT-wt) and Y114 mutant FHIT-expressing (Ad-FHIT-Y114F) adenoviruses. Among 12 distinct proteins that exhibited 4-fold differences in expression on comparison of the two infected cell lysates, cyclophilin A, the intracellular reporter of the immunosuppressive drug cyclosporine A, showed a remarkably decreased protein level in cells infected with Ad-FHIT-wt versus Ad-FHIT-Y114F. Conversely, loss of Fhit expression resulted in increased cyclophilin A expression in mouse tissues and cell lines. Restoration of Fhit expression led to down-regulated cyclophilin A protein expression and subsequently prevented cyclophilin A-induced up-regulation of cyclin D1, Cdk4, and resultant cell cycle progression (G(1)-S transition), which was independent of Ca(2+)/calmodulin-dependent kinase inhibitor, KN-93. Interestingly, Fhit down-modulation of phosphatase activity of calcineurin, which controls cyclin D1/Cdk4 activation, was reversed by cyclophilin A treatment in a concentration-dependent manner, a reversal that was inhibited by additional cyclosporine A treatment. Thus, cyclophilin A is a downstream target in Fhit-mediated cessation of cell cycle progression at late G(1) phase. Elucidation of the protein effectors of Fhit signaling may lead to identification of targets for lung cancer therapy.
Insights
Loss of fragile histidine triad (Fhit) protein suppresses tumors by downregulating cyclophilin A, a key factor in cell cycle progression. Restoring Fhit halts cancer cell growth by targeting cyclophilin A signaling.
Area of Science:
- Molecular Biology
- Cancer Research
- Proteomics
Background:
- Fragile histidine triad (Fhit) protein acts as a tumor suppressor, but its specific signaling pathways remain unclear.
- Fhit's tumor suppressor function is diminished by a Y114F substitution, indicating the importance of this residue.
Purpose of the Study:
- To identify proteins involved in Fhit-mediated tumor suppression using a proteomic approach.
- To investigate the role of cyclophilin A in Fhit's tumor suppressor pathway.
Main Methods:
- Proteomic analysis of lung cancer cells expressing wild-type and Y114F mutant Fhit.
- Western blotting to assess protein expression levels.
- Cell cycle analysis to evaluate the impact on cell cycle progression.
Main Results:
- Cyclophilin A protein levels were significantly decreased in cells expressing wild-type Fhit compared to Y114F mutant Fhit.
- Loss of Fhit expression led to increased cyclophilin A, which in turn promoted cyclin D1 and Cdk4 expression, driving cell cycle progression.
- Restoration of Fhit expression down-regulated cyclophilin A, inhibiting cell cycle progression at the G1-S transition.
- Fhit's modulation of calcineurin phosphatase activity was reversed by cyclophilin A, highlighting cyclophilin A as a downstream target.
Conclusions:
- Cyclophilin A is a downstream target in the Fhit-mediated tumor suppression pathway, specifically affecting cell cycle progression at the late G1 phase.
- Understanding Fhit signaling and its protein effectors, like cyclophilin A, may reveal new therapeutic targets for lung cancer.
Related Concept Videos
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
